Status:
NOT_YET_RECRUITING
Clinical Trial of Comparing DA-5222 Single-administration and Co-administration of DA-5222-R1, DA-5222-R2 and DA-5222-R3 in Healthy Adult Subjects
Lead Sponsor:
Dong-A ST Co., Ltd.
Conditions:
Healthy
Eligibility:
All Genders
19+ years
Phase:
PHASE1
Brief Summary
This study is to compare pharmacokinetics and safety profiles of DA-5222 single-administration and co-administration of DA-5222-R1, DA-5222-R2 and DA-5222-R3 in healthy adult subjects
Eligibility Criteria
Inclusion
- Healthy volunteers
- BMI between 18 and 30 kg/m2
- Body weight: Male≥50kg, Female≥45kg
- Subjects who have signed an informed consent themselves after receiving detailed explanation about clinical study
Exclusion
- Subjects with clinically significant medical history
- Subjects with history of drug abuse or addicted
- Subjects with allergy or drug hypersensitivity
Key Trial Info
Start Date :
June 1 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 1 2025
Estimated Enrollment :
48 Patients enrolled
Trial Details
Trial ID
NCT06993181
Start Date
June 1 2025
End Date
July 1 2025
Last Update
June 6 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Bumin Hospital
Seoul, South Korea, South Korea, 07590